Preview
Full Doc
 | 2003 |
Technology Transfer and Manufacturing Agreement
Technology Transfer and Manufacturing Agreement (102K)
Doc #172168: Click preview link for longer preview.
TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT
This TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT, effective as of this 3rd day of October 2003 (the "Effective Date"), between DISCOVERY LABORATORIES, INC., a Delaware corporation ("Discovery"), having its principal place of business at 350 South Main Street, Suite 307, Doylestown, PA 18901, and LAUREATE PHARMA, L.P., a Delaware limited partnership ("Laureate"), having a principal place of business at 201 College Road East, Princeton, NJ 08540, (each a "Party", collectively the "Parties").
W I T N E S S E T H:
WHEREAS, Laureate possesses capabilities relating to the manufacture of sterile pharmaceutical products.
WHEREAS, Laureate provides a full range of processing services to the pharmaceutical industry, including process development, bioanalytical chemistry, microparticle production, formulation, aseptic filling and Quality Control testing.
WHEREAS, Discovery desires Laureate to perform services in accordance with the terms of this Agreement and the Scope (as hereinafter defined) related to the scale up, validation and manufacture of SurfaxinTM clinical and commercial supplies, and Laureate desires to perform such services.
NOW, THEREFORE, in consideration of the above statements and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereto agree as follows:
Section 1. Definitions. Terms defined elsewhere in this Agreement shall have the meanings set forth therein for all purposes of this Agreement unless otherwise specified to the contrary. The following terms shall have the meaning set forth below in this Section 1:
1.1 "Affiliate(s)" for purposes of this Agreement shall mean any Person, firm, trust, partnership, corporation, company or other entity or combination thereof which directly or indirectly: (i) controls a party; (ii) is controlled by a Party; or (iii) is under common control with a Party. As used in this definition, the terms "control" and "controlled" shall mean ownership of fifty percent (50%) or more (including ownership by trusts with substantially the same beneficial interests) of the voting and equity rights of such person, firm, trust, partnership, corporation, company or other entity or combination thereof or the power to direct the management of such person, firm, trust, corporation or other entity or combination thereof.
1.2 "Agreement" means this document as signed by the Parties including the Scope and any referenced attachments and any amendments and additions to this document or such attachments.
1.3 "Assumptions" shall have the meaning as set forth in Section 9.
TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT
1 {PAGE}
1.4 "Batch" means formulated Drug Product yielding a quantity of bulk volume and/or vials manufactured at the same time and identified by a unique lot number.
1.5 "Batch Record" means all associated documentation utilized for manufacturing a Batch generated by Laureate and approved by Discovery made concurrently with the performance of each step of the manufacturing process for the Drug Product, such that successive steps in such processes may be traced.
1.6 "Claim" shall have the meaning set forth in Section 19(a).
1.7 "Contaminants" shall have the meaning set forth in Section 19(c).
1.8 "Discovery Confidential Information" means any and all Discovery proprietary information concerning the Drug Substance or Drug Product previously not known to Laureate and supplied by Discovery to Laureate, and related processes, technologies, compounds, inventions, Discovery Know-How show-how, designs, specifications, formulas, methods, samples, biological, chemical or other materials, medical or other devices, developmental or experimental work, improvements, discoveries, research and clinical or other data, databases, software, manuals, internal policies and procedures, patent applications, licenses, term sheets, prices, costs, financial information, budgets, projections, marketing, and selling and business plans, provided that such information is not developed jointly with Laureate or its employees or other personnel.
1.9 "Discovery Know How" means all scientific, technical and other information relating to the Drug Substance or Drug Product known to Discovery from time-to-time other than Laureate Confidential Information.
1.10 "Drug Product" means the final formulated dosage form pharmaceutical medicine containing Drug Substance and Other Active Ingredients, manufactured in accordance with cGMP and conforming to Specifications, that Discovery or its Affiliates will use for clinical trials and commercialization requirements.
1.11 "Drug Substance" means the Surfaxin peptide otherwise known as KL4 or sinapultide) in unformulated bulk form, to be supplied by Discovery's Third-Party raw material suppliers, manufactured in accordance with cGMP and conforming to Specifications.
1.12 "Excipients" means those inactive ingredients presently used in the Process that are not intended to exert therapeutic effects (i.e., [***]."
1.13 "Facility" or "Facilities" means either or both, as the case may be, of Laureate's manufacturing facilities located at 201 College Road East, Princeton, NJ 08540 or 710 Union Boulevard, Totowa, NJ 07512.
1.14 "FDA" shall mean the United States Food and Drug Administration.
1.15 "Filling Components" means vials, stoppers and crimps (overseals) used for an aseptic fill of the Drug Product.
Information marked by [***] has been omitted pursuant to a request for confidential treatment. The omitted portion has been separately filed with the Securities and Exchange Commission.
172168
|
Akorn
As referenced in this Technology Transfer and Manufacturing Agreement:
Akorn, – successful installation, validation and start-up at Laureate's Facility
of the Drug Product manufacturing line located previously at the manufacturing
facility of Akorn, Inc. The Parties currently contemplate that the installation
and setup of such manufacturing line at the Facility will be completed by
September _____________
Akorn; – sole expense,
shall arrange for the transfer to Laureate, installation and validation of its
current manufacturing line now maintained at the facilities of Akorn; (ii)
during the development phase of the Program(as described in Section 2(b)(ii),
certain equipment related to the scaled-up _____________
Akorn – and "Aseptic Filling
Services" for Drug Product.
b. A complete copy of a representative executed Batch Record for
Drug Product previously manufactured by Akorn including
without limitation, all Process information, Specifications
for Drug Product and all Materials, test methods and results.
c. A copy of the sections _____________
dt 91321
;
Discovery Labs
As referenced in this Technology Transfer and Manufacturing Agreement:
DISCOVERY LABORATORIES, – TRANSFER AND MANUFACTURING AGREEMENT
This TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT, effective as of this 3rd
day of October 2003 (the "Effective Date"), between DISCOVERY LABORATORIES,
INC., a Delaware corporation ("Discovery"), having its principal place of
business at 350 South Main Street, Suite 307, Doylestown, PA 18901, and _____________
Discovery Laboratories, – the date after delivery if sent by
overnight carrier; or (iii) on the date received if sent by certified mail.
If to Discovery
Discovery Laboratories, Inc.
350 S. Main St., Suite 307
Doylestown, PA 18901
Attn: Legal Department
Telefax: (215) 340-3940
With a copy to:
Dickstein _____________
DISCOVERY LABORATORIES, – LAUREATE PHARMA, L.P.
By: Laureate Pharma, Inc., its general partner
------------------------------------------
By: Robert J. Broeze
Name: Robert J. Broeze, Ph.D.
Title: President
DISCOVERY LABORATORIES, INC.
By: Robert J. Capetola
------------------------------------------
Name: Robert J. Capetola, Ph.D.
Title: President and Chief Executive Officer
TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT
_____________
dt 206565
;
Dickstein
As referenced in this Technology Transfer and Manufacturing Agreement:
Dickstein Shapiro – 307
Doylestown, PA 18901
Attn: Legal Department
Telefax: (215) 340-3940
With a copy to:
Dickstein Shapiro Morin & Oshinsky LLP
1177 Avenue of the Americas, 41st Floor
New York, NY 10036-
dt 35730
;
|
Lowenstein
As referenced in this Technology Transfer and Manufacturing Agreement:
Lowenstein Sandler – Attn: Robert J. Broeze, Ph.D., President
Telefax: (609) 520-3963
With a copy to:
Lowenstein Sandler PC
65 Livingston Avenue
Roseland, NJ 07068-1791
Attn: John D. Hogoboom
Telefax: (973)
dt 38148
;
Laureate Pharma, L.P.
|
Preview
Full Doc
 | 2003 |
Contract Manufacturing Agreement
Contract Manufacturing Agreement (76K)
Doc #172188: Click preview link for longer preview.
CONTRACT MANUFACTURING AGREEMENT
BY AND BETWEEN
LAUREATE PHARMA L.P.
AND
CYTOGEN CORPORATION
DATED
JANUARY 15, 2003
{PAGE}
TABLE OF CONTENTS
Page
1. Definitions..........................................................1
2. Commencement; Expiration.............................................6
3. Consideration........................................................7
4. Payments.............................................................8
5. Performance of Services; Other Assistance; FDA Fees.................12
6. Manufacturing and Testing; Approvals; SOPs..........................13
7. Materials Delivery; Testing.........................................15
8. Payment Dates; Late Payments........................................19
9. Renovation Schedule; Regulatory Matters and Approvals; Order Dates........................................................20
10. Stability Testing; Shipping.........................................22
11. Cytogen's Covenants, Representation and Warranties..................23
12. Laureate's Covenants, Representations and Warranties; Limited Liability..................................................24
13. Indemnities.........................................................28
14. Contact Individuals.................................................30
15. No Biohazards.......................................................30
16. Termination.........................................................30
17. Insurance...........................................................32
18. Confidentiality.....................................................33
19. Notices.............................................................34
20. Non-Exclusivity.....................................................35
{PAGE}
21. Entire Agreement....................................................36
22. Governing Law.......................................................36
23. Assignment..........................................................36
24. Independent Contractors.............................................37
25. No Waiver...........................................................37
26. Force Majeure.......................................................37
27. Third Parties.......................................................37
28. Interpretation......................................................38
29. Singular Terms......................................................38
30. Headings............................................................38
31. Counterparts........................................................38
32. Severability........................................................39
ii
{PAGE}
MANUFACTURING AGREEMENT -----------------------
MANUFACTURING AGREEMENT, dated January 15, 2003, by and between CYTOGEN CORPORATION, a Delaware corporation ("Cytogen") and LAUREATE PHARMA L.P., a Delaware limited partnership ("Laureate").
W I T N E S S E T H : --------------------
WHEREAS, Cytogen wishes to engage the services of Laureate to produce Filled ProstaScint Product and Filled Sodium Acetate Product (each as hereinafter defined) in accordance with the provisions hereof.
NOW, THEREFORE, it is agreed as follows:
1. Definitions. The following terms shall have the meanings specified in this paragraph 1. Other terms are defined in this Agreement and, throughout this Agreement, those terms shall have the meanings respectively ascribed to them.
(a) "Affiliate" means, with respect to a party, any individual or entity which controls, is controlled by or is under common control with such party. For purposes of this definition, "control" means an equity or income interest of fifty percent (50%) or more in, or the possession, directly or indirectly, of the power to cause the direction of the management, activities or policies of such individual or entity, whether through the ownership of voting securities or other equity interest, by contract or otherwise.
{PAGE} (b) "Batch" means (i) with respect to CYT-351, the specific quantity of CYT-351 which is produced as a result of the performance of a single [**] hollow-fiber run; (ii) with respect to CYT-356, the specific quantity of CYT-356 which is produced from the conjugation of a Batch of CYT-351, or the conjugation of a specified identified portion of a Batch of CYTll-351 or the conjugation of combined batches of CYT-351; and (iii) with respect to sodium acetate buffer solution, the specific quantity of sodium acetate buffer solution produced during the course of a single manufacturing run.
(c) ""Cytogen SOPs" means Cytogen's written standard operating procedures to be utilized in connection with the manufacture, production and in-process release testing of CYT-351, Filled ProstaScint Product and Filled Acetate Product.
(d) "Cytogen Supplied Materials" means all ingredients, raw materials, resins, components and supplies, except for water and facility derived process gasses, required in connection with the production by Laureate of CYT-351, Filled ProstaScint Product or Filled Sodium Acetate Product.
(e) "CYT-351" means the monoclonal antibody intermediate product which is used in manufacturing ProstaScint.
(f) "CYT-356" means the immunoconjugated form of CYT-351 (sometimes referred to in the course of manufacture and production of Filled ProstaScint Product as bulk ProstaScint).
2 {PAGE}
(g) "Facility" means Laureate's manufacturing and filling premises located in Princeton, New Jersey.
(h) "Facility Fee" means the fee for facility access and utilization provided for in paragraph 3(a).
(i) "FDA" means the United States Food and Drug Administration and shall include any division or center thereof.
(j) "Filled Sodium Acetate Product" means vials filled with sodium acetate solution from an identified Lot which are in a form ready for release and shipment from the Facility.
(k) "Filled ProstaScint Product" means the vials filled with CYT-356 from an identified Lot which are in a form ready for release and shipment from the Facility.
(l) "cGMP" means current Good Manufacturing Practices for the manufacture and testing of pharmaceutical materials, as specified in the Code of Federal Regulations and associated regulatory agency guidelines as currently interpreted and practiced by Laureate at the Facility.
(m) "Incoming Acceptance Tests" means, with respect to each Cytogen Supplied Material, the analysis or testing thereof supplied to Laureate by Cytogen pursuant to paragraph 6(b) hereof and to be performed by Laureate in order to determine whether or not such Cytogen Supplied Product conforms to the applicable approved Specifications.
172188
|
Chadbourne
As referenced in this Contract Manufacturing Agreement:
Chadbourne & Parke – Road East
Princeton, NJ 08540
Fax No.: 1-609-520-3963
With a copy to
Chadbourne & Parke LLP
30 Rockefeller Plaza
New York, NY 10112
Attn: Stuart D. Baker
Fax No.: 1-
dt 34761
;
Hale and Dorr
As referenced in this Contract Manufacturing Agreement:
Hale and Dorr – Princeton, NJ 08540
Fax No.: 1-609-452-2317
34
{PAGE}
With a copy to:
Hale and Dorr LLP
650 College Road East
Princeton, NJ 08540
Fax No.: 1-609-750-7700
dt 37148
;
| Laureate Pharma L.P.;
Cytogen Corp.
|
Preview
Full Doc
 | 2003 |
Manufacturing Agreement
Manufacturing Agreement (74K)
Doc #172217: Click preview link for longer preview.
VIASYSTEMS, INC.
MANUFACTURING AGREEMENT
This agreement (this "Agreement") is made this 21st day of September, 2001 between Viasystems, Inc., a Delaware corporation ("VIASYSTEMS"), and SR Telecom S.A.S., a French corporation ("S.A.S.") and SR Telecom Inc., a corporation incorporated pursuant to the laws of Canada. For the purposes of this Agreement, SR Telecom Inc. and S.A.S. are collectively referred to as the "Buyer".
RECITALS
The parties desire to establish the terms and conditions that will apply to Buyer's purchase of certain products manufactured by Viasystems for Buyer. Buyer desires to have certain products of its design manufactured by Viasystems for sale to Buyer. Viasystems has the capability of manufacturing such products in its Rouen Facilities or in any other Viasystems facility and desires to do so for sale to Buyer.
AGREEMENT
In consideration of the foregoing and the agreements contained herein, the parties agree as follows:
1. DEFINITIONS.
a) "Affiliate" shall mean any entity that directly or indirectly controls, is under control with, or is controlled by, one of the parties to this Agreement. An entity shall be deemed to be in control of another entity only if, and for so long as, it owns or controls more than fifty-one percent (51%) of the shares of the subject entity entitled to vote in the election of the directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority).
b) "Confidential Information" of a party shall mean any information disclosed by that party to the other pursuant to this Agreement which is written, graphic, machine readable or other tangible form and is marked "Confidential," "Proprietary" or in some other manner to indicate its confidential nature. Confidential Information may also include oral information disclosed by one party to the other pursuant to this Agreement, provided that such information is designated as confidential at the time of disclosure and is reduced to writing by the disclosing party within a reasonable time (not to exceed thirty (30) days) after its oral disclosure), and such writing is marked in a manner to indicate its confidential nature and delivered to the receiving party. Notwithstanding any failure to so identify it, however, all Specifications shall be Confidential Information of Viasystems.
{PAGE}
c) "Cost" shall mean the actual purchase price of a component, its production or a service and does not include an administrative or similar mark-up.
d) "Delivery Date" shall mean a date of which delivery of Products is requested in a Purchase Order and accepted by Viasystems.
e) "Distribution Item" shall mean a component that is included in a Buyer stocking agreement with a third party distributor that is held in the distributor's stock and available for immediate shipment to Buyer or its authorized manufacturer.
f) "Excess Inventory" shall mean materials, components and supplies purchased under the terms of this agreement, held in inventory by Viasystems and for which there is no requirement in the next 90 days of the forecast.
g) "Intellectual Property" shall mean (i) all rights held by Buyer in the Products and in its Confidential Information, including, but not limited to, patents, copyrights, authors' rights, trademarks, tradenames, know-how and trade secrets, irrespective of whether such rights arise under U.S. or international intellectual property, unfair competition or trade secret laws, and (ii) all rights held by Viasystems in its Confidential Information, including, but not limited to, patents, copyrights, authors' rights, trademarks, tradenames, know-how and trade secrets, irrespective of whether such rights arise under U.S. or international intellectual property, unfair competition of trade secret laws.
h) "Inventory" shall mean raw materials, components and supplies necessary for the manufacture of Products pursuant to this Agreement.
i) "Long-Lead Inventory" shall mean those items of Inventory identified in writing by Viasystems to Buyer prior to beginning manufacture of any particular type of Product that have a lead time from Viasystems' supplier longer than ninety (90) days.
j) "Products" shall mean all products designed and/or marketed by Buyer or its Affiliates included in Exhibit A hereto and any modification or replacement thereof or substitution therefore.
k) "Purchase Order" shall mean a Buyer Purchase Order in the form mutually agreed by the parties.
l) "Services" shall mean the manufacturing services set forth in Exhibit B hereto.
m) "Specifications" shall mean the written specifications for the Products as provided by Buyer and accepted by Viasystems, and as revised from time to time upon mutual agreement of the
172217
|
SR Telecom
As referenced in this Manufacturing Agreement:
SR Telecom Inc – of September,
2001 between Viasystems, Inc., a Delaware corporation ("VIASYSTEMS"), and SR
Telecom S.A.S., a French corporation ("S.A.S.") and SR Telecom Inc ., a
corporation incorporated pursuant to the laws of Canada. For the purposes of
this Agreement, SR Telecom Inc. and S.A.S. _____________
SR Telecom Inc – corporation ("S.A.S.") and SR Telecom Inc., a
corporation incorporated pursuant to the laws of Canada. For the purposes of
this Agreement, SR Telecom Inc . and S.A.S. are collectively referred to as the
"Buyer".
RECITALS
The parties desire to establish the terms and conditions that _____________
SR TELECOM INC – Sr VP
Address:______________________ Address: 101 S. Hanley, Suite 400
______________________ St. Louis, MO 63105
Fax Number:___________________ Fax Number: (314) 746-2251
SR TELECOM INC .
VP Finance ICFO
By: /s/ Pierre St-Arnaud
--------------------------
Name: Pierre St-Arnaud
------------------------
(print)
Title: President and CEO
Address:______________________
______________________
Fax:_________________________
_____________
dt 277149
;
Viasystems, Inc.;
| SR Telecom S.A.S.
|
Preview
Full Doc
 | 2003 |
Letter Agreement
Letter Agreement (14K)
Doc #172244: Click preview link for longer preview.
March 12, 2003
AMS Electronics Ltd. 41 Hataasia Street Arad
Dear Sirs,
In connection with the Manufacturing and Purchase Agreement entered into between AMS Electronics Ltd. (AMS), Nexus Telocation Systems Ltd. (Nexus Telocation) and Nexus Data Inc. and Nexus Data (1993) Ltd. (collectively, Nexus Data), dated January 15, 2002 (the Original Manufacturing Agreement; capitalized terms used herein and not specifically otherwise defined shall have the meaning ascribed to them in the Original Manufacturing Agreement); and , and further to our correspondence to this matter we would like to put in writing our understanding regarding the changes and amendments to the Original Manufacturing Agreement.
WHEREAS,
Nexus Telocation and AMS signed a letter agreement amending the Original Manufacturing Agreement on January 27, 2003 (the Prior Amendment); and
WHEREAS
Nexus Telocation and AMS agree to terminate the Prior Amendment and it shall be replaced in its entirety by this letter agreement; and
WHEREAS
Nexus Telocation has sold all its holdings in Nexus Data on December 24, 2002, to third parties, subject to certain conditions, and since such sale has already been completed, Nexus Data is no longer a subsidiary of Nexus Telocation; and
WHEREAS
AMS reached separate agreements with Nexus Telocation and Nexus Data in such a way that the Original Manufacturing Agreement shall continue to apply with each of Nexus Telocation and Nexus Data separately such that each of Nexus Telocation and Nexus Data shall only be responsible for its liabilities; and
WHEREAS
Nexus Telocation and AMS reached an agreement regarding certain changes to the terms of the Original Manufacturing Agreement as herein detailed; and
WHEREAS
the parties wish to set forth their agreements with respect to the Original Manufacturing Agreement as it shall continue to apply to and between Nexus Telocation and AMS;
Now therefore, it is agreed to amend the terms of the Original Manufacturing Agreement between Nexus Telocation and AMS as follows:
172244
|
Nexus Telocation
As referenced in this Letter Agreement:
Nexus Telocation Systems Ltd – Electronics Ltd.
41 Hataasia Street
Arad
Dear Sirs,
In connection with the Manufacturing and Purchase Agreement entered into between AMS Electronics Ltd. (AMS), Nexus Telocation Systems Ltd . (Nexus Telocation) and Nexus Data Inc. and Nexus Data (1993) Ltd. (collectively, Nexus Data), dated January 15, 2002 (the Original Manufacturing Agreement; _____________
Nexus Telocation Systems Ltd – except for the provisions of the following Sections of the Original Manufacturing Agreement which shall be deleted and amended as specified above.
Sincerely,
Nexus Telocation Systems Ltd .
Yaron Sheinman - Chairman of the Board
Shlomo Sadovsky - CEO
The undersigned, AMS Electronics Ltd., hereby agrees to the above detailed changes to _____________
dt 276975
;
| AMS Electronics Ltd.
|
Preview
Full Doc
 | 2003 |
Development and Manufacturing Agreement
Development and Manufacturing Agreement (52K)
Doc #172281: Click preview link for longer preview.
Original Copy USAT/RadiSys Confidential
This Development and Manufacturing Agreement (DMA), is made on the date signed (following section 3.19) between RadiSys Corporation and
USA Technologies, Inc. 200 Plant Avenue Wayne, PA., 19087-3520 USA
RadiSys Corporation (RadiSys) and USA Technologies, Inc, (USAT) agree to act within the following terms stated in this DMA, which will remain in effect until either party terminates the DMA as provided herein,
RECITALS
A. USAT desires that RadiSys: (1) in the Development Stage, develop the product described in Appendix I (the Product) that USAT plans to sell, and (2) after completion of the Development Stage, manufacture and sell the Product that USAT requires, in the Manufacturing Stage.
B. Both parties intend the development and manufacture of the Product to be an interactive process. Communication and the free flow of information between the parties will be critical. It is anticipated that frequent and detailed communication will be required from project kick-off through end of life of the product. The required communication shall include technical discussions, design decisions, and status reporting. The expected communication channels include email, telephone, video, fax, and teleconferencing. Unless otherwise tn specified, no in-person meetings between RadiSys and USAT are required,
C. In addition, both parties anticipate that specifications and schedules will be amended and updated over time. Thus, the parties intend the DMA to accommodate such changes and agree to make good faith and reasonable efforts to resolve any disputes that may arise.
AGREEMENT
1.0 DEVELOPMENT STAGE
Section I of the DMA is effective from date of execution through the first delivery of a Production Release product.
1.1 Product definition
1.1.1 Specifications. The Product is described in the RadiSys Product Proposal, as Appendix 1. This Appendix defines the base-line specification for
PAGE I
{PAGE} Original Copy USAT/RadiSys Confidential
the Product and defines the project scope. Detailed functional and design specification will be developed as the Product is developed. Changes to the Specifications may be made as provided herein.
1.1.2 Product Stages. The following product stages will have the following functionality and levels of verification:
Prototypes: A small number of units (quantity determined in proposal and documented in Appendix table A3-1) will be assembled and tested by RadiSys. Basic functionality would be checked before the first prototype is shipped to a customer, but full functionality would not be verified and very little stress testing would be carried out. Hardware prototypes may contain blue wires and may have functional and mechanical limitations but they would be suitable for software development and initial integration. Prototype units would not be supported once the next revision of the hardware is available and would not be covered by the RadiSys warranty.
Limited Production Product: A Limited Production product would be fully representative of Production Release product, with any exception(s) agreed upon in advance with USAT. Limited Production units would be suitable for system testing, regulatory testing or certification, and for sampling to customers, and would be covered by the standard product warranty, as provided in Section 3.4.
Production Release Product: These units would meet all Specifications and would be covered under the product warranty, as provided in Section 3.4.
1.2 Development and Payment Schedule; Purchase Order
1.2.1 Schedules. RadiSys will use commercially reasonable efforts to develop the Product, and USAT agrees to make payments, both in accordance with the development and payment schedules set forth in Appendices 3. Appendix 3 identifies the Pre payment schedules, product pricing, and service pricing relating to this project. Appendix 4 is the high-level project schedule which shows project milestones. In addition, it identifies the parties responsible for performing and approving the completion. Appendices 5 and 6 provide scheduled lists of items required of both RadiSys and USAT for project completion. Changes may be made to Development Schedule as provided herein.
1.2.2 Purchase Order. USAT shall submit an authorized purchase order to RadiSys for any product or service (including NRE) to be delivered by
172281
|
USA Technologies
As referenced in this Development and Manufacturing Agreement:
USA Technologies, Inc – USAT/RadiSys Confidential
This Development and Manufacturing Agreement (DMA), is made on the date
signed (following section 3.19) between RadiSys Corporation and
USA Technologies, Inc .
200 Plant Avenue
Wayne, PA., 19087-3520
USA
RadiSys Corporation (RadiSys) and USA Technologies, Inc, (USAT) agree to
act within the following _____________
USA Technologies, Inc – following section 3.19) between RadiSys Corporation and
USA Technologies, Inc.
200 Plant Avenue
Wayne, PA., 19087-3520
USA
RadiSys Corporation (RadiSys) and USA Technologies, Inc , (USAT) agree to
act within the following terms stated in this DMA, which will remain in
effect until either party terminates the _____________
USA Technologies, Inc – to
the laws of the State of New York exclusive of choice of law rules.
----------------------------- ------------------------------
(Name) (Date) (Name) (DAte)
(Title) (Title)
RadiSys Corporation USA Technologies, Inc .
PAGE 16
{PAGE}
Original Copy USAT/RadiSys Confidential
Addendum A: Software license agreements
Includes a license to RadiSys provided code (computing BIOS, _____________
dt 272607
;
| RadiSys Corporation
|
Preview
Full Doc
 | 2003 |
Contract Manufacturing Agreement
Contract Manufacturing Agreement (37K)
Doc #225283: Click preview link for longer preview.
CONTRACT MANUFACTURING AGREEMENT
THIS CONTRACT MANUFACTURING AGREEMENT is made and entered into between Boehringer Ingelheim Vetmedica, Inc., a Delaware corporation (the "Manufacturer") and KMG Bernuth, Inc., a Delaware corporation (the "Customer"), on this 30th day of December, 2002 (the "Effective Date").
RECITALS
WHEREAS, Contemporaneously with the execution of this Agreement, Customer has acquired from Manufacturer under the terms of the Asset Purchase Agreement, the Manufacturer's business of producing and selling the Products;
WHEREAS, Manufacturer has significant experience in manufacturing the Products;
WHEREAS, Customer has agreed to purchase the raw materials inventory necessary to manufacture the Products and Customer desires to retain Manufacturer, under the terms and conditions described herein, to manufacture the Products;
WHEREAS, Customer has acquired the Equipment necessary to manufacture the Products and such Equipment is currently housed within the Manufacturer's facility; and
NOW, THEREFORE, in consideration of the premises and mutual promises, terms and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties, intending to be legally bound, do hereby agree as follows:
SECTION 1: DEFINITIONS.
1.1 Definitions. Unless context otherwise requires, capitalized terms shall have the meaning set forth in the Definitions attached hereto as EXHIBIT A, which is incorporated herein by reference.
SECTION 2: REPRESENTATIONS OF CUSTOMER.
Customer hereby makes the following representations and warranties to Manufacturer, each of which shall be true as of the Effective Date and throughout the Term:
2.1 Authorization to Conduct Business; Certification. Customer is duly authorized to transact business in the manner contemplated by this Agreement.
2.2 Authority. Customer has full corporate power and authority to enter into and perform (a) this Agreement; and (b) all documents and instruments to be executed by Customer pursuant to this Agreement. This Agreement has been duly executed and delivered by Customer and is enforceable in accordance with its terms.
2.3 Consents; Licenses. No consent, authorization, license, order or approval of, or filing or registration with, any governmental authority or other Person is required for the execution and delivery by Customer of this Agreement and the consummation by Customer of the transactions contemplated by this Agreement.
2.4 Declaration by Customer. Customer declares that Customer has complied with all federal, state and local laws regarding business permits, certificates and licenses that may be required to sell and distribute the Products.
2.5 Litigation. There is no pending litigation, which would materially impact or affect this Agreement or Customer's execution or performance hereof.
225283
| |
Armstrong
As referenced in this Contract Manufacturing Agreement:
Armstrong Teasdale – Suite 402
Houston, TX 77036
Attn: John V. Sobchak
Fax: 713-988-9298
Copy to:
Armstrong Teasdale LLP
Copy to:
Roger C. Jackson, Esq.
One Metropolitan Square, Suite 2600
St. Louis,
dt 29286
|
Preview
Full Doc
 | 2003 |
Technology Transfer and Manufacturing Agreement
Technology Transfer and Manufacturing Agreement (102K)
Doc #283652: Click preview link for longer preview.
TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT
This TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT, effective as of this 3rd day of October 2003 (the "Effective Date"), between DISCOVERY LABORATORIES, INC., a Delaware corporation ("Discovery"), having its principal place of business at 350 South Main Street, Suite 307, Doylestown, PA 18901, and LAUREATE PHARMA, L.P., a Delaware limited partnership ("Laureate"), having a principal place of business at 201 College Road East, Princeton, NJ 08540, (each a "Party", collectively the "Parties").
W I T N E S S E T H:
WHEREAS, Laureate possesses capabilities relating to the manufacture of sterile pharmaceutical products.
WHEREAS, Laureate provides a full range of processing services to the pharmaceutical industry, including process development, bioanalytical chemistry, microparticle production, formulation, aseptic filling and Quality Control testing.
WHEREAS, Discovery desires Laureate to perform services in accordance with the terms of this Agreement and the Scope (as hereinafter defined) related to the scale up, validation and manufacture of SurfaxinTM clinical and commercial supplies, and Laureate desires to perform such services.
NOW, THEREFORE, in consideration of the above statements and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereto agree as follows:
Section 1. Definitions. Terms defined elsewhere in this Agreement shall have the meanings set forth therein for all purposes of this Agreement unless otherwise specified to the contrary. The following terms shall have the meaning set forth below in this Section 1:
1.1 "Affiliate(s)" for purposes of this Agreement shall mean any Person, firm, trust, partnership, corporation, company or other entity or combination thereof which directly or indirectly: (i) controls a party; (ii) is controlled by a Party; or (iii) is under common control with a Party. As used in this definition, the terms "control" and "controlled" shall mean ownership of fifty percent (50%) or more (including ownership by trusts with substantially the same beneficial interests) of the voting and equity rights of such person, firm, trust, partnership, corporation, company or other entity or combination thereof or the power to direct the management of such person, firm, trust, corporation or other entity or combination thereof.
1.2 "Agreement" means this document as signed by the Parties including the Scope and any referenced attachments and any amendments and additions to this document or such attachments.
1.3 "Assumptions" shall have the meaning as set forth in Section 9.
TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT
1 {PAGE}
1.4 "Batch" means formulated Drug Product yielding a quantity of bulk volume and/or vials manufactured at the same time and identified by a unique lot number.
1.5 "Batch Record" means all associated documentation utilized for manufacturing a Batch generated by Laureate and approved by Discovery made concurrently with the performance of each step of the manufacturing process for the Drug Product, such that successive steps in such processes may be traced.
1.6 "Claim" shall have the meaning set forth in Section 19(a).
1.7 "Contaminants" shall have the meaning set forth in Section 19(c).
1.8 "Discovery Confidential Information" means any and all Discovery proprietary information concerning the Drug Substance or Drug Product previously not known to Laureate and supplied by Discovery to Laureate, and related processes, technologies, compounds, inventions, Discovery Know-How show-how, designs, specifications, formulas, methods, samples, biological, chemical or other materials, medical or other devices, developmental or experimental work, improvements, discoveries, research and clinical or other data, databases, software, manuals, internal policies and procedures, patent applications, licenses, term sheets, prices, costs, financial information, budgets, projections, marketing, and selling and business plans, provided that such information is not developed jointly with Laureate or its employees or other personnel.
1.9 "Discovery Know How" means all scientific, technical and other information relating to the Drug Substance or Drug Product known to Discovery from time-to-time other than Laureate Confidential Information.
1.10 "Drug Product" means the final formulated dosage form pharmaceutical medicine containing Drug Substance and Other Active Ingredients, manufactured in accordance with cGMP and conforming to Specifications, that Discovery or its Affiliates will use for clinical trials and commercialization requirements.
1.11 "Drug Substance" means the Surfaxin peptide otherwise known as KL4 or sinapultide) in unformulated bulk form, to be supplied by Discovery's Third-Party raw material suppliers, manufactured in accordance with cGMP and conforming to Specifications.
1.12 "Excipients" means those inactive ingredients presently used in the Process that are not intended to exert therapeutic effects (i.e., [***]."
1.13 "Facility" or "Facilities" means either or both, as the case may be, of Laureate's manufacturing facilities located at 201 College Road East, Princeton, NJ 08540 or 710 Union Boulevard, Totowa, NJ 07512.
1.14 "FDA" shall mean the United States Food and Drug Administration.
1.15 "Filling Components" means vials, stoppers and crimps (overseals) used for an aseptic fill of the Drug Product.
Information marked by [***] has been omitted pursuant to a request for confidential treatment. The omitted portion has been separately filed with the Securities and Exchange Commission.
TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT
2 {PAGE}
1.16 "Filled Product" means vials filled with Drug Product from an identified Lot or Lots that are in a form ready for release and shipment from the Facility.
1.17 "Good Manufacturing Practices" or "GMP" or "cGMP" means current good manufacturing practices, as specified in regulations promulgated from time to time by the FDA for the manufacture and testing of pharmaceutical products. Laureate's operational quality standards are defined in internal cGMP policy documents and are based on Laureate's current interpretation of cGMP.
1.18 "Laureate Confidential Information" means any information, business, technical or financial data concerning Laureate's manufacturing processes and techniques including without limitation, Laureate Know How, previously not known to Discovery and related processes, technologies, compounds, inventions, Laureate Know-How, show-how, designs, specifications, formulas, methods, samples, biological, chemical or other materials, medical or other devices, developmental or experimental work, improvements, discoveries, research and clinical or other data, databases, software, manuals, internal policies and procedures, patent applications, licenses, term sheets, prices, costs, financial information, budgets, projections, marketing, and selling and business plans provided that such information is not developed jointly with Discovery or its employees.
1.19 "Laureate Group" shall have the meaning set forth in Section 19(b).
1.20 "Laureate Know How" means all scientific, technical and other information
283652
|
Akorn
As referenced in this Technology Transfer and Manufacturing Agreement:
Akorn, – successful installation, validation and start-up at Laureate's Facility
of the Drug Product manufacturing line located previously at the manufacturing
facility of Akorn, Inc. The Parties currently contemplate that the installation
and setup of such manufacturing line at the Facility will be completed by
September _____________
Akorn; – sole expense,
shall arrange for the transfer to Laureate, installation and validation of its
current manufacturing line now maintained at the facilities of Akorn; (ii)
during the development phase of the Program(as described in Section 2(b)(ii),
certain equipment related to the scaled-up _____________
Akorn – and "Aseptic Filling
Services" for Drug Product.
b. A complete copy of a representative executed Batch Record for
Drug Product previously manufactured by Akorn including
without limitation, all Process information, Specifications
for Drug Product and all Materials, test methods and results.
c. A copy of the sections _____________
dt 227200
;
Discovery Labs
As referenced in this Technology Transfer and Manufacturing Agreement:
DISCOVERY LABORATORIES, – TRANSFER AND MANUFACTURING AGREEMENT
This TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT, effective as of this 3rd
day of October 2003 (the "Effective Date"), between DISCOVERY LABORATORIES,
INC., a Delaware corporation ("Discovery"), having its principal place of
business at 350 South Main Street, Suite 307, Doylestown, PA 18901, and _____________
Discovery Laboratories, – the date after delivery if sent by
overnight carrier; or (iii) on the date received if sent by certified mail.
If to Discovery
Discovery Laboratories, Inc.
350 S. Main St., Suite 307
Doylestown, PA 18901
Attn: Legal Department
Telefax: (215) 340-3940
With a copy to:
Dickstein _____________
DISCOVERY LABORATORIES, – LAUREATE PHARMA, L.P.
By: Laureate Pharma, Inc., its general partner
------------------------------------------
By: Robert J. Broeze
Name: Robert J. Broeze, Ph.D.
Title: President
DISCOVERY LABORATORIES, INC.
By: Robert J. Capetola
------------------------------------------
Name: Robert J. Capetola, Ph.D.
Title: President and Chief Executive Officer
TECHNOLOGY TRANSFER AND MANUFACTURING AGREEMENT
_____________
dt 236750
;
Dickstein
As referenced in this Technology Transfer and Manufacturing Agreement:
Dickstein Shapiro – Discovery Laboratories, Inc.
350 S. Main St., Suite 307
Doylestown, PA 18901
Attn: Legal Department
Telefax: (215) 340-3940
With a copy to:
Dickstein Shapiro Morin & Oshinsky LLP
1177 Avenue of the Americas, 41st Floor
New York, NY 10036-2714
Attn: Ira L. Kotel
Telefax: (212) 997- _____________
dt 214320
;
|
Lowenstein
As referenced in this Technology Transfer and Manufacturing Agreement:
Lowenstein Sandler – P.
201 College Road East
Princeton, NJ 08540
Attn: Robert J. Broeze, Ph.D., President
Telefax: (609) 520-3963
With a copy to:
Lowenstein Sandler PC
65 Livingston Avenue
Roseland, NJ 07068-1791
Attn: John D. Hogoboom
Telefax: (973) 597-2400
Section 26. Choice of Law. This _____________
dt 234630
;
Laureate Pharma, L.P.
|
Preview
Full Doc
 | 2003 |
Contract Manufacturing Agreement
Contract Manufacturing Agreement (76K)
Doc #287726: Click preview link for longer preview.
CONTRACT MANUFACTURING AGREEMENT
BY AND BETWEEN
LAUREATE PHARMA L.P.
AND
CYTOGEN CORPORATION
DATED
JANUARY 15, 2003
{PAGE}
TABLE OF CONTENTS
Page
1. Definitions..........................................................1
2. Commencement; Expiration.............................................6
3. Consideration........................................................7
4. Payments.............................................................8
5. Performance of Services; Other Assistance; FDA Fees.................12
6. Manufacturing and Testing; Approvals; SOPs..........................13
7. Materials Delivery; Testing.........................................15
8. Payment Dates; Late Payments........................................19
9. Renovation Schedule; Regulatory Matters and Approvals; Order Dates........................................................20
10. Stability Testing; Shipping.........................................22
11. Cytogen's Covenants, Representation and Warranties..................23
12. Laureate's Covenants, Representations and Warranties; Limited Liability..................................................24
13. Indemnities.........................................................28
14. Contact Individuals.................................................30
15. No Biohazards.......................................................30
16. Termination.........................................................30
17. Insurance...........................................................32
18. Confidentiality.....................................................33
19. Notices.............................................................34
20. Non-Exclusivity.....................................................35
{PAGE}
21. Entire Agreement....................................................36
22. Governing Law.......................................................36
23. Assignment..........................................................36
24. Independent Contractors.............................................37
25. No Waiver...........................................................37
26. Force Majeure.......................................................37
27. Third Parties.......................................................37
28. Interpretation......................................................38
29. Singular Terms......................................................38
30. Headings............................................................38
31. Counterparts........................................................38
32. Severability........................................................39
ii
{PAGE}
MANUFACTURING AGREEMENT -----------------------
MANUFACTURING AGREEMENT, dated January 15, 2003, by and between CYTOGEN CORPORATION, a Delaware corporation ("Cytogen") and LAUREATE PHARMA L.P., a Delaware limited partnership ("Laureate").
W I T N E S S E T H : --------------------
WHEREAS, Cytogen wishes to engage the services of Laureate to produce Filled ProstaScint Product and Filled Sodium Acetate Product (each as hereinafter defined) in accordance with the provisions hereof.
NOW, THEREFORE, it is agreed as follows:
1. Definitions. The following terms shall have the meanings specified in this paragraph 1. Other terms are defined in this Agreement and, throughout this Agreement, those terms shall have the meanings respectively ascribed to them.
(a) "Affiliate" means, with respect to a party, any individual or entity which controls, is controlled by or is under common control with such party. For purposes of this definition, "control" means an equity or income interest of fifty percent (50%) or more in, or the possession, directly or indirectly, of the power to cause the direction of the management, activities or policies of such individual or entity, whether through the ownership of voting securities or other equity interest, by contract or otherwise.
{PAGE} (b) "Batch" means (i) with respect to CYT-351, the specific quantity of CYT-351 which is produced as a result of the performance of a single [**] hollow-fiber run; (ii) with respect to CYT-356, the specific quantity of CYT-356 which is produced from the conjugation of a Batch of CYT-351, or the conjugation of a specified identified portion of a Batch of CYTll-351 or the conjugation of combined batches of CYT-351; and (iii) with respect to sodium acetate buffer solution, the specific quantity of sodium acetate buffer solution produced during the course of a single manufacturing run.
(c) ""Cytogen SOPs" means Cytogen's written standard operating procedures to be utilized in connection with the manufacture, production and in-process release testing of CYT-351, Filled ProstaScint Product and Filled Acetate Product.
(d) "Cytogen Supplied Materials" means all ingredients, raw materials, resins, components and supplies, except for water and facility derived process gasses, required in connection with the production by Laureate of CYT-351, Filled ProstaScint Product or Filled Sodium Acetate Product.
(e) "CYT-351" means the monoclonal antibody intermediate product which is used in manufacturing ProstaScint.
(f) "CYT-356" means the immunoconjugated form of CYT-351 (sometimes referred to in the course of manufacture and production of Filled ProstaScint Product as bulk ProstaScint).
2 {PAGE}
(g) "Facility" means Laureate's manufacturing and filling premises located in Princeton, New Jersey.
(h) "Facility Fee" means the fee for facility access and utilization provided for in paragraph 3(a).
(i) "FDA" means the United States Food and Drug Administration and shall include any division or center thereof.
(j) "Filled Sodium Acetate Product" means vials filled with sodium acetate solution from an identified Lot which are in a form ready for release and shipment from the Facility.
(k) "Filled ProstaScint Product" means the vials filled with CYT-356 from an identified Lot which are in a form ready for release and shipment from the Facility.
(l) "cGMP" means current Good Manufacturing Practices for the manufacture and testing of pharmaceutical materials, as specified in the Code of Federal Regulations and associated regulatory agency guidelines as currently interpreted and practiced by Laureate at the Facility.
(m) "Incoming Acceptance Tests" means, with respect to each Cytogen Supplied Material, the analysis or testing thereof supplied to Laureate by Cytogen pursuant to paragraph 6(b) hereof and to be performed by Laureate in order to determine whether or not such Cytogen Supplied Product conforms to the applicable approved Specifications.
3 {PAGE}
(n) "Laureate SOPs" means Laureate's written standard operation procedures utilized by Laureate in connection with its operational activities at the Facility.
(o) "Lot" means a Batch or a specific identified portion of a Batch of CYT-356 or sodium acetate, as applicable, which is produced in the course of Laureate's performance of a single manufacturing production run.
(p) "Manufacturing Procedures" means the activities, processes, procedures and instructions provided to Laureate by Cytogen pursuant to paragraph 6(a) hereof and to be utilized by Laureate in the production of CYT-351, Filled ProstaScint Product and Filled Sodium Acetate Product.
(q) "On Hand CYT" means the quantity of CYT-351 in the possession of Cytogen on the date hereof and to be supplied by Cytogen to Laureate in connection with Laureate's performance of the Primary Production Campaign.
(r) "Optional Production Campaign" means Laureate's performance of (i) up to two (2) [**] hollow fiber runs to the end of producing CYT-351, (ii) against Cytogen's order therefor, Laureate's performance of up to two (2) conjugations of the quantity of CYT-351 produced pursuant to Laureate performance of the [**] hollow fiber runs referenced in clause (i) of this definition to the end of producing ProstaScint including all Services to supply Cytogen with Filled ProstaScint Product and (iii) against Cytogen's order therefor, Laureate's performance of up to two (2) sodium acetate fills, each fill utilizing a volume of sodium acetate buffer solution as specified in the Batch record to the end of supplying Cytogen with Filled Sodium Acetate Product.
4 {PAGE}
(s) "Primary Production Campaign" means Laureate's performance of (i) two (2) conjugation runs utilizing the On Hand CYT to the end of producing ProstaScint including all Services to supply Cytogen with Filled ProstaScint Product and (ii) two (2) sodium acetate fills, each fill utilizing a volume of sodium acetate buffer solution as specified in the Batch record including all Services to the end of supplying Cytogen with Filled Sodium Acetate Product.
(t) "ProstaScint" means the compound capromab pendetide formulated by conjugating the murine monoclonal antibody CYT-351 to the linker-chelator glycl-tyrosyl-(N-diethyltriaminepentaacetic acid)-lysine hydrochloride.
(u) "Services" means the activities undertaken by Laureate in the course of Laureate's performance of the Primary Production Campaign and, if applicable, the Optional Production Campaign or any part thereof.
287726
|
Chadbourne
As referenced in this Contract Manufacturing Agreement:
Chadbourne & Parke – Phd.
President
Laureate Pharma L.P.
201 College Road East
Princeton, NJ 08540
Fax No.: 1-609-520-3963
With a copy to
Chadbourne & Parke LLP
30 Rockefeller Plaza
New York, NY 10112
Attn: Stuart D. Baker
Fax No.: 1-212-541-5369
20. Non-Exclusivity. (a) Laureate _____________
dt 214036
;
|
Hale and Dorr
As referenced in this Contract Manufacturing Agreement:
Hale and Dorr – and Development
Cytogen Corporation
650 College Road East
Princeton, NJ 08540
Fax No.: 1-609-452-2317
34
{PAGE}
With a copy to:
Hale and Dorr LLP
650 College Road East
Princeton, NJ 08540
Fax No.: 1-609-750-7700
If to Laureate:
Robert J. Broeze, Phd.
President
_____________
dt 218365
;
Laureate Pharma L.P.
|
Preview
Full Doc
 | 2003 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222401
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528644
|
Preview
Full Doc
 | 2003 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222402
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528645
|
Preview
Full Doc
 | 2003 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222403
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528646
|
Preview
Full Doc
 | 2003 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222404
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528647
|
Preview
Full Doc
 | 2003 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222405
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528648
|
Preview
Full Doc
 | 2003 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222406
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528649
|
Preview
Full Doc
 | 2003 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222407
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The LOEMMA shall
remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- -----------------------------
Title: Title:
--------------------------- -----------------------------
Date: Date:
--------------------------- -----------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528650
|
Full Doc
 | 2002 |
License and OEM Manufacturing Agreement
License and OEM Manufacturing Agreement (194K)
Doc #288197: This document is immediately available for purchase, but does not have a preview available for viewing.
LICENSE AND OEM MANUFACTURING AGREEMENT
This License and OEM Manufacturing Agreement (the "Agreement") is made and effective as of this 1st day of July, 2002, by and among EchoStar Satellite Corporation ("ESC"), having a place of business at 5701 S. Santa Fe Drive, Littleton, Colorado 80120, EchoStar Technologies Corporation ("ETC"), having a place of business at 90 Inverness Circle East, Englewood, Colorado 80112, and Thomson multimedia Inc. ("Licensee"), having a place of business at 10330 North Meridian Street, Indianapolis, Indiana 46290.
INTRODUCTION
This Agreement confirms the terms and conditions upon which: (i) Licensee shall manufacture and sell (under license from ETC) Licensee Receivers to Licensee Retailers, (ii) Licensee shall manufacture and sell (under license from ETC) ETC Receivers to ETC, and (iii) ETC shall manufacture and sell OEM Receivers to Licensee.
1. DEFINITIONS
In addition to any other defined terms in this Agreement and except as otherwise expressly provided for in this Agreement, the following terms shall have the following meanings:
1.1 "Accessories" means a remote control, antenna, LNB, feedarm and related components, as such components may change from time to time in ETC's sole judgment.
1.2 "Activate" means the authorization of a Smart Card to permit a Receiver to access DISH Network programming.
1.3 "Additional Revenue Receivers" shall have the meaning ascribed to that term in Section 1.20 below.
1.4 "Affiliate" shall mean, with respect to a party, any person or entity directly or indirectly controlling, controlled by, or under common control with such party.
1.5 "Business Rule" means any term, requirement, condition, condition precedent, process or procedure associated with a Promotional Program or otherwise identified as a Business Rule associated with a Promotional Program by ESC, which is communicated to Licensee by ESC or any Affiliate of ESC. ESC reserves the right, in its sole discretion, to modify any Business Rule at any time by providing Licensee with ***.
-1-
*** Certain confidential portions of this exhibit were omitted by means of redacting a portion of the text. Copies of the exhibit containing the redacted portions have been filed separately with the Securities and Exchange Commission subject to a request for confidential treatment pursuant to Rule 24.b-2 under the Securities Exchange Act. {PAGE}
1.6 "Certificate Program" means any Promotional Program offered by ESC wherein (i) Licensee purchases a serialized certificate (a "Promotional Certificate") from ESC or an Affiliate of ESC for resale directly to a Licensee Retailer, (ii) the Licensee Retailer purchases the Promotional Certificate from Licensee for resale directly to an end-user, and (iii) the Promotional Certificate, among other things, entitles the end-user to a Receiver (or the use of a Receiver, if the program involves leasing the Receiver to the end-user) and installation of the Receiver.
1.7 "DBS" shall mean direct broadcast satellite.
1.8 "Design Review" shall mean a review conducted between ETC and Licensee to establish whether Licensee's implementation of the Licensee Receiver complies with the ETC Receiver Specifications.
1.9 "DISH Network" shall mean the DBS network owned and operated in the United States by ESC and its Affiliates.
1.10 "EchoStar Parties" shall mean ETC and ESC.
1.11 "Eligible Programming" means the then-current DISH Network programming packages for which ESC pays a monthly incentive to its retailers generally, which programming packages may change at any time and from time to time in the sole judgment of ESC.
1.12 "ETC Marks" shall mean trademarks, service marks and trade names owned by ETC and/or its Affiliates or for which ETC and/or its Affiliates have the right to grant a sublicense.
1.13 "ETC Receiver Specifications" shall mean those specifications defining DISH Network broadcast reception requirements, Receiver performance requirements, Receiver mechanical configuration, and other Receiver form, fit, look, feel and function as specified by ETC from time to time.
1.14 "ETC Receivers" shall mean Receivers that are manufactured in strict conformance with the ETC Receiver Specifications by Licensee or on behalf of Licensee by *** and branded with such trademarks as ETC may designate from time to time in its sole judgment,
1.15 "ETC Technology" shall have the meaning ascribed to that term in Section 2.1 below.
1.16 "Integrated Receivers" shall have the meaning ascribed to that term in Section 1.20 below.
288197
|
Thomson
As referenced in this License and OEM Manufacturing Agreement:
Thomson multimedia – Fe Drive,
Littleton, Colorado 80120, EchoStar Technologies Corporation ("ETC"), having a
place of business at 90 Inverness Circle East, Englewood, Colorado 80112, and
Thomson multimedia Inc. ("Licensee"), having a place of business at 10330 North
Meridian Street, Indianapolis, Indiana 46290.
INTRODUCTION
This Agreement confirms the terms and conditions _____________
Thomson multimedia – of such notice (in
the case of delivery by mail or by overnight courier service) shall constitute
the giving thereof:
If to Licensee: Thomson multimedia Inc.
10330 North Meridian St. ***
Indianapolis, IN 46290
Attn: David Spomer, Vice President
***
With a copy to: Thomson multimedia, Inc.
10330-No. Meridian _____________
Thomson multimedia, – thereof:
If to Licensee: Thomson multimedia Inc.
10330 North Meridian St. ***
Indianapolis, IN 46290
Attn: David Spomer, Vice President
***
With a copy to: Thomson multimedia, Inc.
10330-No. Meridian St.
Indianapolis, IN 46290
Attn: Jay Wagner, Associate General Counsel
If to ETC: EchoStar Technologies Corporation
90 Inverness _____________
THOMSON MULTIMEDIA – By:
-----------------------------------------
David K. Moskowitz
Senior Vice President and General Counsel
ECHOSTAR TECHNOLOGIES CORPORATION
By:
-----------------------------------------
David K. Moskowitz
Senior Vice President and General Counsel
THOMSON MULTIMEDIA INC. (LICENSEE)
By:
-----------------------------------------
David Spomer
Vice President
-58-
*** Certain confidential portions of this exhibit were omitted by means of
redacting a portion of _____________
dt 222408
;
|
Thomson
As referenced in this License and OEM Manufacturing Agreement:
Thomson multimedia Inc – Fe Drive,
Littleton, Colorado 80120, EchoStar Technologies Corporation ("ETC"), having a
place of business at 90 Inverness Circle East, Englewood, Colorado 80112, and
Thomson multimedia Inc . ("Licensee"), having a place of business at 10330 North
Meridian Street, Indianapolis, Indiana 46290.
INTRODUCTION
This Agreement confirms the terms and conditions _____________
Thomson multimedia Inc – of such notice (in
the case of delivery by mail or by overnight courier service) shall constitute
the giving thereof:
If to Licensee: Thomson multimedia Inc .
10330 North Meridian St. ***
Indianapolis, IN 46290
Attn: David Spomer, Vice President
***
With a copy to: Thomson multimedia, Inc.
10330-No. Meridian _____________
Thomson multimedia, Inc – thereof:
If to Licensee: Thomson multimedia Inc.
10330 North Meridian St. ***
Indianapolis, IN 46290
Attn: David Spomer, Vice President
***
With a copy to: Thomson multimedia, Inc .
10330-No. Meridian St.
Indianapolis, IN 46290
Attn: Jay Wagner, Associate General Counsel
If to ETC: EchoStar Technologies Corporation
90 Inverness Circle _____________
THOMSON MULTIMEDIA INC – By:
-----------------------------------------
David K. Moskowitz
Senior Vice President and General Counsel
ECHOSTAR TECHNOLOGIES CORPORATION
By:
-----------------------------------------
David K. Moskowitz
Senior Vice President and General Counsel
THOMSON MULTIMEDIA INC . (LICENSEE)
By:
-----------------------------------------
David Spomer
Vice President
-58-
*** Certain confidential portions of this exhibit were omitted by means of
redacting a portion of _____________
dt 528651
|
Preview
Full Doc
 | 2002 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- ------------------------------
Title: Title:
--------------------------- ------------------------------
Date: Date:
--------------------------- ------------------------------
Thomson multimedia Inc.
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222409
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
--------------------------- ------------------------------
Title: Title:
--------------------------- ------------------------------
Date: Date:
--------------------------- ------------------------------
Thomson multimedia Inc .
By:
---------------------------
Title:
---------------------------
Date:
---------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528652
|
Preview
Full Doc
 | 2002 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
------------------------ ----------------------------
Title: Title:
------------------------ ----------------------------
Date: Date:
------------------------ ----------------------------
Thomson multimedia Inc.
By:
------------------------
Title:
------------------------
Date:
------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222410
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
------------------------ ----------------------------
Title: Title:
------------------------ ----------------------------
Date: Date:
------------------------ ----------------------------
Thomson multimedia Inc .
By:
------------------------
Title:
------------------------
Date:
------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528653
|
Preview
Full Doc
 | 2002 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
-------------------------- -------------------------
Title: Title:
-------------------------- -------------------------
Date: Date:
-------------------------- -------------------------
Thomson multimedia Inc.
By:
--------------------------
Title:
--------------------------
Date:
--------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222411
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
-------------------------- -------------------------
Title: Title:
-------------------------- -------------------------
Date: Date:
-------------------------- -------------------------
Thomson multimedia Inc .
By:
--------------------------
Title:
--------------------------
Date:
--------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528654
|
Preview
Full Doc
 | 2002 | |
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc. is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
-------------------------- ---------------------------
Title: Title:
-------------------------- ---------------------------
Date: Date:
-------------------------- ---------------------------
Thomson multimedia Inc.
By:
--------------------------
Title:
--------------------------
Date:
--------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 222412
;
|
Thomson
As referenced in this OEM Manufacturing Agreement:
Thomson multimedia Inc – and OEM Manufacturing Agreement ("LOEMMA") with an
effective date of July 1, 2002, by and among EchoStar Satellite Corporation,
EchoStar Technologies Corporation and Thomson multimedia Inc . is hereby amended
as follows:
1. Section 11.16 is amended to read:
The Parties shall mutually agree to a trademark agreement ( _____________
Thomson multimedia Inc – the LOEMMA. The
LOEMMA shall remain in all other respects unchanged.
EchoStar Satellite Corporation EchoStar Technologies Corporation
By: By:
-------------------------- ---------------------------
Title: Title:
-------------------------- ---------------------------
Date: Date:
-------------------------- ---------------------------
Thomson multimedia Inc .
By:
--------------------------
Title:
--------------------------
Date:
--------------------------
{/TEXT}
{/DOCUMENT} _____________
dt 528655
|